Acute hepatitis B

Acute hepatitis B is an acute viral hepatitis caused by hepatitis B virus (HBV) ^[1]. The supplied sources characterize HBV as an infection of public-health significance worldwide and note that acute hepatitis B may resolve spontaneously but can also evolve into chronic infection ^[2][1]. The evidence provided also situates acute HBV within broader HBV prevention and management discussions, but does not supply additional case-definition detail beyond this etiologic description ^[3].

The source snippets describe acute hepatitis B as usually self-limited, indicating that many cases follow a limited clinical course ^[1]. They also state that some patients develop chronic infection after the acute episode, with younger age at infection identified as a risk factor for chronicity ^[1][2]. Beyond this, the provided material does not give a detailed symptom list, laboratory profile, or complication sequence for acute disease ^[3][1]. Clinical-course information in the sources is therefore conservative and limited primarily to self-limited nature and risk of chronic progression ^[1][3].

HBV is described as a major cause of morbidity and mortality worldwide, and one source notes more than 400 million persons living with chronic hepatitis B, including 1.25 million Americans ^[2]. In the United States, chronic HBV infection is reported to account for about 5,000 annual deaths from cirrhosis and hepatocellular carcinoma ^[2]. The supplied sources also note that routine vaccination since 1982 and infant and childhood vaccination programs introduced in the 1990s have markedly reduced new infections, while universal screening of pregnant women has decreased transmission ^[2][1]. Source-backed detail on the global incidence of acute hepatitis B specifically, outbreak patterns, or regional age distribution is not yet available in the snippets provided ^[3][2].

HBV is found in body fluids and secretions, and the supplied material states that in developed countries it is most commonly transmitted sexually or via intravenous drug use ^[2]. Occupational exposure and perinatal transmission are also mentioned, although they are described as rare in the United States ^[2]. The sources do not provide additional route-specific timing, persistence, or relative transmission efficiencies for acute hepatitis B ^[2][1].

The supplied sources identify susceptible individuals as candidates for prevention efforts and note higher risk of chronic progression among those infected at a younger age ^[3][1]. They also indicate that in developed countries HBV transmission commonly occurs through sexual exposure or intravenous drug use, which implies these are important exposure-linked groups for monitoring ^[2]. Occupational exposure and perinatal exposure are mentioned as additional, though rarer in the United States, contexts of transmission ^[2]. Source-backed detail on other specific high-risk groups is not yet available in the provided material ^[3][1].

Prevention in the supplied sources centers on vaccination and screening. Effective hepatitis B vaccines have been available since 1982, and infant and childhood vaccination programs have been associated with a marked decrease in new infections ^[2]. The material also states that routine vaccination and universal screening of pregnant women have decreased HBV transmission, and that vaccination is recommended for infants and adults at increased risk ^[1][2]. Source-backed detail on post-exposure prophylaxis, household measures, or other exposure-control steps is not yet available in the provided snippets ^[3][1].

For surveillance purposes, acute hepatitis B should be interpreted as the acute presentation of HBV infection within a broader epidemiologic context in which chronic infection is common and remains a major burden ^[1][2]. The supplied literature highlights incidence, clinical course, prevention in susceptible individuals, and management as the main areas of attention, but does not provide a detailed surveillance case definition ^[3]. Because acute disease may be self-limited and some infections progress to chronicity, monitoring should distinguish incident acute infection from the larger reservoir of chronic HBV where possible ^[1][2].

1. 1 Thuener J et al. Hepatitis A and B Infections. Prim Care. 2017 Dec. PMID: 29132524. doi: 10.1016/j.pop.2017.07.005. PubMed: https://pubmed.ncbi.nlm.nih.gov/29132524/
2. 2 Lin KW et al. Hepatitis B. Am Fam Physician. 2004 Jan 1. PMID: 14727820. PubMed: https://pubmed.ncbi.nlm.nih.gov/14727820/
3. 3 Dekker SE et al. Treatment and Prevention of Acute Hepatitis B Virus. Clin Liver Dis. 2021 Nov. PMID: 34593149. doi: 10.1016/j.cld.2021.06.002. PubMed: https://pubmed.ncbi.nlm.nih.gov/34593149/
4. 4 Viral Hepatitis: Acute Hepatitis. Scholarly DOI record. 2019. doi: 10.1007/978-3-030-03535-8. DOI: https://doi.org/10.1007/978-3-030-03535-8
5. 5 Acute hepatitis. Radiopaedia.org. 2021. doi: 10.53347/rid-93042. DOI: https://doi.org/10.53347/rid-93042
6. 6 Acute Hepatitis. Principles and Practice of Pediatric Infectious Diseases. 2012. doi: 10.1016/b978-1-4377-2702-9.00062-3. DOI: https://doi.org/10.1016/b978-1-4377-2702-9.00062-3

ICD-10

B16

ICD-11

1E50.1

Total cases

10K

Peak month

2003-04

Coverage

2 reporting countries · 2000-01-01 → 2026-05-01